PTC Therapeutics (PTCT) Stock: Here’s What You Need To Know

PTC Therapeutics (NASDAQ:PTCT) On Monday, PTC Therapeutics fell by 40% to $7.97 per share after the company had announced that the FDA refused its appeal for a refuse-to-file letter. PTC Therapeutics has not been able to get the FDA to back its Duchenne Muscular Dystrophy — DMD — drug. What happened was that PTC had … Read more

Biotech Stock News (CMRX) (PTCT) (SRPT) (BMRN) (PPHM)

Chimerix (NASDAQ:CMRX)  On Monday February 22, 2016 shares of Chimerix tumbled by 40% as the company announced that two phase 3 trials had to be stopped because of lack of efficacy. The phase 3 trial, known as the SUPPRESS trial, recruited a total of 452 patients. The patients that were recruited in the trial were … Read more